Pseudomyxoma peritonei
Conditions
Interventions
Cisplatin Group:The patients are intravenously injected with 5-FU (400 mg/m2) before the operation. Perform CRS+HIPEC. After completing CRS, the patient underwent cisplatin HIPEC treatment. Add 120 mg
Cisplatin + Docetaxel Group:The patients are intravenously injected with 5-FU (400 mg/m2) before the operation. Perform CRS+HIPEC. After completing CRS, the patient underwent HIPEC treatment with cisp
Sponsors
Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: General consideration: patients aged 18 years (inclusive) -75 years old with a primary diagnosis of pseudomyxoma peritonei who meet the following inclusion criteria and do not meet the exclusion criteria is eligible for enrollment in this study. (1) Age 18-75 years old, regardless of gender and race; (2) Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment; (3) KPS score >= 60, with expected survival time more than 12 months; (4) The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function; (5) No history of allergy to biological products; (6) No serious bacterial or viral infection; (7) Non-pregnancy and lactation; (8) The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment.
Exclusion criteria
Exclusion criteria: (1) Highly allergic or with a history of severe allergies, especially to biological products; (2) Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination; (3) Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation; (4) T-lymphocyte carcinoma/tumor; (5) Patients with systemic infection or severe local infection requiring anti-infection treatment; (6) Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs; (7) Coagulation disorders (e.g., hemophilia); (8) Infectious diseases (e.g. HIV, RPR, active TB, etc.); (9) Pregnant or lactating women, or women who have pregnancy plans within half a year; (10) Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation; (11) Patients with severe autoimmune diseases; (12) Any life-threatening disease, physical condition or organ system dysfunction that the researcher believes may damage the safety of subjects and expose the research results to unnecessary risks; Drug-dependent persons; (13) Patients and/or authorized family members who refuse or do not actively sign the informed consent; (14) Participants in other clinical studies within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome labeled with 5-FU in tumor specimens; | — |
Countries
China
Contacts
Public ContactYan Li
Beijing Tsinghua Changgung Hospital (School of Clinical Medicine, Tsinghua University)
Outcome results
None listed